PortfoliosLab logoPortfoliosLab logo
ACAD vs. ABBV
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ACAD vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ACADIA Pharmaceuticals Inc. (ACAD) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ACAD achieves a -15.39% return, which is significantly lower than ABBV's 4.43% return. Over the past 10 years, ACAD has underperformed ABBV with an annualized return of -3.24%, while ABBV has yielded a comparatively higher 19.47% annualized return.


ACAD

1D
2.31%
1M
7.11%
YTD
-15.39%
6M
-18.79%
1Y
0.53%
3Y*
-2.67%
5Y*
-2.01%
10Y*
-3.24%

ABBV

1D
2.07%
1M
8.84%
YTD
4.43%
6M
4.29%
1Y
31.92%
3Y*
24.36%
5Y*
19.80%
10Y*
19.47%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ACAD vs. ABBV - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ACAD
ACADIA Pharmaceuticals Inc.
-15.39%45.56%-41.39%96.67%-31.79%-56.34%24.96%164.56%-46.30%4.40%
ABBV
AbbVie Inc.
4.43%33.08%18.86%-0.23%24.01%32.43%27.72%1.47%-0.96%60.07%

Correlation

The correlation between ACAD and ABBV is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.18

Correlation (10Y)
Calculated over the trailing 10-year period

0.24

Correlation (All Time)
Calculated using the full available price history since Jan 2, 2013

0.27

The correlation between ACAD and ABBV shifts across timeframes, from 0.16 (3 years) to 0.27 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ACAD:

$3.90B

ABBV:

$416.46B

EPS

ACAD:

$2.20

ABBV:

$2.05

PE Ratio

ACAD:

10.28

ABBV:

114.38

PS Ratio

ACAD:

3.53

ABBV:

6.63

PB Ratio

ACAD:

3.13

ABBV:

15.14

Total Revenue (TTM)

ACAD:

$1.10B

ABBV:

$62.82B

Gross Profit (TTM)

ACAD:

$758.58M

ABBV:

$46.15B

EBITDA (TTM)

ACAD:

$104.56M

ABBV:

$17.96B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ACAD vs. ABBV — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ACAD
ACAD Risk / Return Rank: 4141
Overall Rank
ACAD Sharpe Ratio Rank: 4343
Sharpe Ratio Rank
ACAD Sortino Ratio Rank: 3838
Sortino Ratio Rank
ACAD Omega Ratio Rank: 3838
Omega Ratio Rank
ACAD Calmar Ratio Rank: 4343
Calmar Ratio Rank
ACAD Martin Ratio Rank: 4242
Martin Ratio Rank

ABBV
ABBV Risk / Return Rank: 7575
Overall Rank
ABBV Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
ABBV Sortino Ratio Rank: 7575
Sortino Ratio Rank
ABBV Omega Ratio Rank: 7373
Omega Ratio Rank
ABBV Calmar Ratio Rank: 7474
Calmar Ratio Rank
ABBV Martin Ratio Rank: 7373
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ACAD vs. ABBV - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ACADABBVDifference
Sharpe ratioReturn per unit of total volatility

-1.26

Sortino ratioReturn per unit of downside risk

-1.61

Omega ratioGain probability vs. loss probability

1.03

1.24

-0.20

Calmar ratioReturn relative to maximum drawdown

0.02

1.85

-1.83

Martin ratioReturn relative to average drawdown

0.03

4.11

-4.08

ACAD vs. ABBV - Sharpe Ratio Comparison

The current ACAD Sharpe Ratio is 0.01, which is lower than the ABBV Sharpe Ratio of 1.27. The chart below compares the historical Sharpe Ratios of ACAD and ABBV, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ACAD vs. ABBV - Drawdown Comparison

The maximum ACAD drawdown since its inception was -96.29%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for ACAD and ABBV.


Loading charts...

Drawdown Indicators


ACADABBVDifference

Max Drawdown

Largest peak-to-trough decline

-96.29%

-45.09%

-51.20%

Max Drawdown (1Y)

Largest decline over 1 year

-27.58%

-17.32%

-10.26%

Max Drawdown (3Y)

Largest decline over 3 years

-57.87%

-20.74%

-37.13%

Max Drawdown (5Y)

Largest decline over 5 years

-57.87%

-21.92%

-35.95%

Max Drawdown (10Y)

Largest decline over 10 years

-77.18%

-45.09%

-32.09%

Current Drawdown

Current decline from peak

-60.35%

-1.66%

-58.69%

Average Drawdown

Average peak-to-trough decline

-50.26%

-10.70%

-39.56%

Ulcer Index

Depth and duration of drawdowns from previous peaks

15.57%

7.78%

+7.79%

Volatility

ACAD vs. ABBV - Volatility Comparison

The current volatility for ACADIA Pharmaceuticals Inc. (ACAD) is 7.65%, while AbbVie Inc. (ABBV) has a volatility of 9.26%. This indicates that ACAD experiences smaller price fluctuations and is considered to be less risky than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ACADABBVDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.65%

9.26%

-1.61%

Volatility (6M)

Calculated over the trailing 6-month period

26.03%

19.11%

+6.92%

Volatility (1Y)

Calculated over the trailing 1-year period

36.80%

25.23%

+11.57%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

55.36%

23.12%

+32.24%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

61.89%

25.83%

+36.06%

Dividends

ACAD vs. ABBV - Dividend Comparison

ACAD has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 2.87%.


PositionTTM20252024202320222021202020192018201720162015
ABBV
AbbVie Inc.
2.87%2.87%3.49%3.82%3.49%3.84%4.41%4.83%3.89%2.65%3.64%3.41%
ACAD
ACADIA Pharmaceuticals Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

ACAD vs. ABBV - Financials Comparison

This section allows you to compare key financial metrics between ACADIA Pharmaceuticals Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
268.06M
15.00B
(ACAD) Total Revenue
(ABBV) Total Revenue
Values in USD except per share items

ACAD vs. ABBV - Profitability Comparison

The chart below illustrates the profitability comparison between ACADIA Pharmaceuticals Inc. and AbbVie Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
83.5%
Portfolio components
ACAD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a gross profit of 0.00 and revenue of 268.06M. Therefore, the gross margin over that period was 0.0%.

ABBV - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.

ACAD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported an operating income of -4.62M and revenue of 268.06M, resulting in an operating margin of -1.7%.

ABBV - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.

ACAD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ACADIA Pharmaceuticals Inc. reported a net income of 3.64M and revenue of 268.06M, resulting in a net margin of 1.4%.

ABBV - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.


Frequently Asked Questions


ACAD and ABBV have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ABBV has higher volatility (9.26%) compared to ACAD (7.65%). In terms of maximum drawdown, ACAD dropped -96.29% vs ABBV's -45.09%.

ABBV currently has the higher Sharpe Ratio (1.27 vs 0.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ACAD and ABBV

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer